Djorwé Soulandi, Bousfiha Amale, Nzoyikorera Néhémie, Nyandwi Joseph, Kawthar Bellamine, Malki Abderrahim
Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco), Avenue Cdt Driss El Harti, Sidi Othman, PB 7955, Casablanca, Morocco.
Bourgogne Laboratory of Medical and Scientific Analysis, 136, Residence Belhcen, Bd Bourgogne, Casablanca, Morocco.
Biomedicine (Taipei). 2023 Sep 1;13(3):31-48. doi: 10.37796/2211-8039.1412. eCollection 2023.
The emergence of SARS-CoV-2 variants has significantly increased the number of cases of COVID-19 among vaccinated individuals, raising concerns about the effectiveness of current vaccines. The aim of this study was to analyze the SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologues and heterologous booster vaccinations with these vaccines, as well as the profiles of reinfected patients.
We analyzed retrospectively 1082 patients vaccinated or unvaccinated with BNT162b2, BBIBP-CorV, and/or ChAdOx1nCoV-19 vaccines to determine their SARS-CoV2 infection statuses using the reverse transcription-polymerase chain reaction (RT-PCR) in addition to their clinical features. The infection risks of patients receiving the different vaccine regimens were compared using multivariate logistic regression analysis, comparing the adjusted OR of a positive COVID-19 test result.
Among 596 vaccinated patients, 53%(n = 286) tested positive for SARS-CoV-2 and 57%(n = 310) tested negative. Among positive cases, 10 were reinfection cases. The risk of SARS-CoV-2 infection was 1.6 (adj. OR) for patients who received one dose compared with those who received two doses (95% CI = 1.3-1.8; p < 0.01).The risk was 2.6 (adj. OR) for patients who received one dose compared with those who received three doses (95%CI = 2.1-3.3; p < 0.01), and 1.6 (adj. OR) for patients who received two doses compared with those who received three doses (95% CI = 1.3-2; p < 0.01). The patients who received two doses that were heterologous to that of the primary vaccine had the lowest risk of infection. Booster vaccinations (third dose) significantly reduced the number of positive cases with an acceptable safety profile. Higher cycle-threshold (Ct) values (indicative of viral load) were observed in vaccinated patients, whereas low Ct values were observed in unvaccinated patients.
A complete cycle of vaccination with homologous vaccines or heterologous vaccines resulted in an acceptable reduction in SARS-CoV-2 infection. Further, vaccination was associated with a reduction in viral load.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株的出现显著增加了接种疫苗个体的新型冠状病毒肺炎(COVID-19)病例数,引发了对当前疫苗有效性的担忧。本研究的目的是分析接种BNT162b2、BBIBP-CorV或ChAdOx1-nCOV-19进行初次疫苗接种后,以及使用这些疫苗进行同源和异源加强接种后的SARS-CoV-2感染风险,以及再次感染患者的情况。
我们回顾性分析了1082例接种或未接种BNT162b2、BBIBP-CorV和/或ChAdOx1nCoV-19疫苗的患者,除了他们的临床特征外,还使用逆转录聚合酶链反应(RT-PCR)来确定他们的SARS-CoV2感染状态。使用多因素逻辑回归分析比较接受不同疫苗接种方案的患者的感染风险,比较COVID-19检测结果为阳性的调整后比值比(OR)。
在596例接种疫苗的患者中,53%(n = 286)的SARS-CoV-2检测呈阳性,57%(n = 310)检测呈阴性。在阳性病例中,有10例为再次感染病例。与接受两剂疫苗的患者相比,接受一剂疫苗的患者感染SARS-CoV-2的风险为1.6(调整后OR)(95%置信区间[CI] = 1.3 - 1.8;p < 0.01)。与接受三剂疫苗的患者相比,接受一剂疫苗的患者风险为2.6(调整后OR)(95%CI = 2.1 - 3.3;p < 0.01),与接受三剂疫苗的患者相比,接受两剂疫苗的患者风险为1.6(调整后OR)(95%CI = 1.3 - 2;p < 0.01)。接受与初次疫苗不同源的两剂疫苗的患者感染风险最低。加强接种(第三剂)显著减少了阳性病例数,且安全性良好。接种疫苗的患者观察到较高的循环阈值(Ct)值(表明病毒载量),而未接种疫苗的患者观察到较低的Ct值。
同源疫苗或异源疫苗的完整接种周期可使SARS-CoV-2感染得到可接受程度的降低。此外,接种疫苗与病毒载量降低有关。